Clinical trial
Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar…
NCT00094549 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00094549 |
|---|---|
| Title | Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder |
| Official title | Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated With Bipolar I Disorder |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Bipolar Disorder |
| Intervention type | Drug |
| Interventions | olanzapine, divalproex sodium, placebo |
| Enrollment | 500 |
| Start date | Oct 1, 2004 |
| Completion | Dec 1, 2006 |
| First posted | Oct 21, 2004 |
| Last update posted | Jan 26, 2007 |
| Countries | Lithuania, Puerto Rico, Romania, Russia, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: